Netherlands-based Aiosyn, a startup developing a diagnostics platform that uses AI to support pathologists with accurate and efficient clinical diagnostics, announced that it has raised €2M in a fresh round of funding.
The round was led by Utrecht-based Health Innovations along with Oost NL, an East Netherlands Development Agency, and Eindhoven-based VC firm LUMO Labs.
Aiosyn claims that the raised funds will help the company to further develop its platform and accelerate the time to market.
In 2021, Aiosyn developed two algorithms as well as set up its certification process. Recently, the company also received ISO:13485 certification, which is a crucial initial step in the development of high-quality AI-based medical devices.
Founded in 2021 and led by CEO Patrick de Boer, Aiosyn aims to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients globally.
Aiosyn says its primary focus is on creating, integrating, and approving AI solutions for clinical diagnostic assistance for difficult-to-diagnose conditions, including breast and prostate cancer.
The startup also provides solutions for businesses in the biotech, pharmaceutical, and diagnostics sectors who want to use AI to enhance their pathological workflows.
Read more on Tech Gist Africa:
Dutch startup Alicia secures €7M
